Melissa B. Epperly, Chief Financial Officer at Zentalis Pharmaceuticals, Inc. (ZNTL), sold 33,982 shares at $43.43 ($1.5M) on 2021-04-05, disclosed to the SEC on 2021-04-06.
Open-market sale of $1.5M ZNTL by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $43.37 | 13,792 | $598K | 40.6% |
| 2 | $43.37 | 13,792 | $598K | 40.6% |
| 3 | $43.43 | 3,083 | $134K | 9.1% |
| 4 | $43.43 | 3,083 | $134K | 9.1% |
| 5 | $44.21 | 149 | $7K | 0.4% |
| 6 | $45.06 | 83 |
| $4K |
| 0.3% |
| Total | $43.39 avg | 33,982 | $1.5M | 100% |
| Filing → |
| ROIV | SELL | 2026-07-01 | $610K | — | Filing → |
| ROIV | SELL | 2026-03-18 | $1.2M | — | Filing → |
| ZNTL | SELL | 2024-02-12 | $29K | — | Filing → |